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Abstract Pituitary adenylate cyclase activating polypeptide
(PACAP) is an endogenous neuropeptide having a widespread
distribution both in the nervous system and peripheral organs
including the female reproductive system. Both the peptide
and its receptors have been shown in the placenta but its role
in placental growth, especially its human aspects, remains
unknown. The aim of the present study was to investigate
the effects of PACAP on invasion, proliferation, cell survival,
and angiogenesis of trophoblast cells. Furthermore, cytokine
production was investigated in human decidual and peripheral
blood mononuclear cells. For in vitro studies, human invasive
proliferative extravillous cytotrophoblast (HIPEC) cells and
HTR-8/SVneo human trophoblast cells were used. Both cell
types were used for testing the effects of PACAP on invasion
and cell survival in order to investigate whether the effects of
PACAP in trophoblasts depend on the examined cell type.
Invasion was studied by standardized invasion assay. PACAP
increased proliferation in HIPEC cells, but not in HTR-8 cells.
Cell viability was examined using MTT test, WST-1 assay,
and annexin V/propidium iodide flow cytometry assay.
Survival of HTR-8/SVneo cells was studied under oxidative
stress conditions induced by hydrogen peroxide. PACAP as
pretreatment, but not as co-treatment, significantly increased
the number of surviving HTR-8 cells. Viability of HIPEC cells
was investigated using methotrexate (MTX) toxicity, but
PACAP1-38 could not counteract its toxic effect.
Angiogenic molecules were determined both in the superna-
tant and the cell lysate by angiogenesis array. In the superna-
tant, we found that PACAP decreased the secretion of various
angiogenicmarkers, such as angiopoietin, angiogenin, activin,
endoglin, ADAMTS-1, and VEGF. For the cytokine assay,
human decidual and peripheral blood lymphocytes were sep-
arated and treated with PACAP1-38. Th1 and Th2 cytokines
were analyzed with CBA assay and the results showed that
there were no significant differences in control and PACAP-
treated cells. In summary, PACAP seems to play various roles
in human trophoblast cells, depending on the cell type and
microenvironmental influences.
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Introduction
Pituitary adenylate cyclase activating polypeptide (PACAP)
belongs to the vasoactive intestinal peptide (VIP)/secretin/
glucagon peptide family. It was first isolated as a hypothalam-
ic peptide based on its effect to influence adenylate cyclase
activity in the pituitary gland (Miyata et al. 1989). PACAP is
widely distributed throughout the entire body including fe-
male reproductive organs (Steenstrup et al. 1995; Ko et al.
1999; Reglodi et al. 2012b; Koves et al. 2014; Csanaky et al.
2014). It occurs in two forms, PACAP1-27 and PACAP1-38,
with PACAP1-38 being the predominant form in mammals.
PACAP exerts its effect through class II G-protein-coupled
receptors. The specific PACAP receptor is called PAC1,
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which binds VIP with much less affinity, while VPAC1 and
VPAC2 receptors have similar high affinity for VIP and
PACAP (Laburthe and Couvineau 2002; Laburthe et al.
2007; Lutz et al. 1999; Muller et al. 2007; Vaudry et al.
2009). Both PACAP1-38 and PACAP1-27, as well as their
receptors have been found in the human pregnant uterus and
placenta (Koh et al. 2005; Scaldaferri et al. 2000). PACAP has
been shown to cause a concentration-dependent relaxation on
stem villi and intramyometrial arteries, suggesting a
vasoregulatory role in the uteroplacental unit (Steenstrup
et al. 1996). PACAP has been suggested to play a role in
decidualization, and the time-related localization of
endometrial-uterine PACAP has been implicated in facilita-
tion of endometrial blood flow (Spencer et al. 2001a, b).
PACAP knockout mice have decreased fertility, described in
numerous studies (Reglodi et al. 2012a). This is in part due to
impaired implantation (Isaac and Sherwood 2008; Koh et al.
2003) in addition to other deficiencies described in mice
lacking endogenous PACAP (Reglodi et al. 2012a).
Previously, we have investigated the levels of both
PACAP isoforms in first trimester and full-term human
placentas (Brubel et al. 2010). Both PACAP1-38 and
PACAP1-27 could be detected in different parts of the
full-term human placenta. Increasing PACAP1-38 content
was measured in the placenta during pregnancy, both on
the maternal and the fetal side. PACAP has been shown to
influence cell survival of various cell types against harmful
stimuli. In most experiments, PACAP enhances cell survival
(Vaudry et al. 2009; Reglodi et al. 2011; Racz et al. 2010;
Horvath et al. 2010; Fabian et al. 2012). However,
investigating the effect of PACAP on survival of different
cell types, cell survival-decreasing effect or no effect could
also be detected depending on the examined cell type, PACAP
concentrations, and other factors present (Li et al.
2006; Wojcieszak and Zawilska 2014; D’Amico et al.
2013; Horvath et al. 2011). Based on this background, it
can be expected that PACAP has an effect on trophoblast
cells of other origins and on placental growth. In our
previous experiments, PACAP enhanced the survival-
decreasing effect of H2O2-induced oxidative stress in JAR
human choriocarcinoma cells (Boronkai et al. 2009). The
first aim of our study was to examine whether the effect of
PACAP in trophoblast cells depends on the type of the
cells. Therefore, we tested the effect of PACAP on cell
viability of HTR-8/Svneo, nontumorous primary trophoblast
cells. Trophoblast cells, with their invasive capability, play
a pivotal role during the implantation of blastocyst in the
early phase of gestation. Therefore, the second aim of the
present study was to investigate whether PACAP influences
the invasiveness and angiogenesis of human trophoblast
cells. Moreover, we examined the effect of PACAP on
decidual lymphocytes and compared it with that of periph-
eral blood mononuclear cells. The common goal of our
experiments was to examine whether there is a relationship
between PACAP and different cell types related to human
pregnancy.
Materials and Methods
Cell Lines
HTR-8/SVneo Cells
Human extravillous trophoblast-derived cell line HTR-8/
SVneo was a generous gift of Charles Graham (Department
of Anatomy and Cell biology, Queen’s University, Kingston,
ON, Canada L7L 3 N6). HTR-8/SVneo cells were cultured in
RPMI (Invitrogen Life Technologies, Carlsbad, CA, USA)
supplemented with 10 % fetal bovine serum (PAA, Csertex
Kft. Hungary).
HIPEC 65
Human invasive, proliferative extravillous cytotrophoblast
cell line (HIPEC) 65 was a generous gift from Pr. D Evain-
Brion, Paris. These primary cells were transformed with sim-
ian virus 40 large T antigen for studying cell invasion (Pavan
et al. 2003). HIPEC 65 cells were cultured in DMEM high
glucose/Ham F-12 (1/1) supplemented with 10 % fetal bovine
serum (FBS, Biochrom AG (Oxoid AG, Basel, Switzerland))
and antibiotic mixture (100 U/ml penicillin, 100 μg/ml strep-
tomycin) (Invitrogen, Basel, Switzerland) at 37 °C in a hu-
midified, 5 % CO2 atmosphere.
Experiments with HTR-8/SVneo Cells
Cell Viability
HTR-8/SVneo cells were plated on 96-well microplate at a
density of 3×104 per well. To investigate the effect of PACAP,
PACAP1-38 was added either simultaneously or prior to
oxidative stress evoking H2O2. Cells were assigned to one of
the experimental groups: (1) control group of cells (no treat-
ment); (2) and (3) cells exposed to 10 or 100 nM PACAP1-38
alone simultaneously or 2 h before starting the H2O2 treat-
ment; (4) cells treated with 150 μMH2O2 for 24 h; (5) and (6)
cells either co-treated with 10 or 100 nM PACAP1-38 and
150 μM H2O2 for 24 h or pretreated with 10 or 100 nM
PACAP1-38 for 2 h then with 150 μM H2O2 for 24 h.
Following the treatments, viability of the HTR-8/SVneo
cells was determined by colorimetric MTT assay (3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide,
Sigma, Hungary), based on the reduction of MTT into a blue
formazan dye by viable mitochondria. At the end of the
treatments, cells were washed twice with phosphate-buffered
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saline (PBS, Sigma), then incubated with PBS containing
0.5 mg/ml of MTT for 3 h at 37 °C in an atmosphere of 5 %
CO2. The solution was aspirated carefully and 200 μl of
dimethylsulfoxide (Sigma, Hungary) was added to dissolve
the blue-colored formazan particles and absorbance was mea-
sured by an ELISA reader (Dialab Kft., Hungary) at 570 nm
representing the values in arbitrary unit (AU).
Invasion Assay of HTR-8/SVneo Cells
The invasiveness of HTR-8/SVneo cells was assessed
by using Oris™ Cell Invasion and Detection Assay
(Platypus Technologies, Madison, WI, USA) according
to the manufacturer’s instructions. Briefly, 96-well plates
were coated with basement membrane extract (BME,
3 mg/ml) and wells were populated with Cell Seeding
Stoppers to restrict cell seeding to the outer annular
regions; then seeded with 75,000 cells. Stoppers were
removed after 24 h, resulting in an unseeded region in
the center of each well (i.e., the detection zone). Cells
were overlaid with 10 mg/ml BME containing 15 %
FBS, then media with or without 1 μM PACAP1-38
was added to the wells. After 72 h, cells were labeled
with calcein AM and the detection zone was analyzed
by an Olympus Fluoview FV-1000 confocal microscope.
Cell invasion was analyzed by measuring the area of the
detection zones using ImageJ analysis software. Invasion
was determined by area closure which was calculated as
follows: invaded area of detection zone/full area of
detection zone×100.
Angiogenesis Array
HTR-8/SVneo cells were treated with 1 μM PACAP1-38 for
24 h. Supernatants of PACAP1-38 treated or untreated HTR-
8/SVneo cells were analyzed by Human Angiogenesis Array
(R&D Systems, Biomedica Hungaria, Budapest, Hungary).
This array is based on binding between sample proteins and
carefully selected captured antibodies spotted on nitrocellu-
lose membranes. The supernatants were collected as described
by the manufacturer. The kit contains all buffers, detection
antibodies, and membranes necessary for the measurements.
The array was performed as described by the manufacturer.
Briefly, after blocking the array membranes for 1 h and adding
the reconstituted detection antibody cocktail for another 1 h at
room temperature, the membranes were incubated with 1 ml
of cellular extracts or 500 μl supernatant at 2–8 °C overnight
on a rocking platform. After washing with buffer three times
and adding of horseradish peroxidase-conjugated streptavidin
to each membrane, we exposed them to a chemiluminescent
detection reagent. Array data on developed X-ray film were
quantitated by ImageJ software.
Experiments with HIPEC 65 Cells
Cell Viability Tests
HIPEC 65 cells were seeded into 96-well plates at a density of
104 cell/well and cultured in medium overnight before the
experiment. HIPEC cells were randomly assigned to one of
the four experimental groups: (1) control group of cells, (2)
100 nM PACAP1-38, (3) 10 μM MTX, and (4) pretreatment
with 100 nM PACAP1-38 followed by 10 μM MTX.
After 48 h of treatment, viability of HIPEC cells was
determined by colorimetric WST-1 assay. The medium was
removed, and fresh DMEM/FCS containing 0.5 % of the
water-soluble WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium) solution was added.
Cells were then incubated for 3 h at 37 °C in an atmosphere
of 5 % CO2. After 3 h of incubation, optical densities were
determined by an ELISA reader (Anthos Labtech 2010;
Vienna, Austria) at the wavelength of 550 nm representing
the values in AU. All experiments were run in four parallels
and repeated six times. Results are expressed as percentage of
control values.
Cell viability was also investigated by annexin V–
propidium iodide staining. By conjugating a fluorescent group
to annexin V, apoptosis can be quantitatively detected using
flow cytometry. The ratio of apoptosis was evaluated after
double staining with fluorescein isothiocyanate (FITC)-la-
beled annexin V and propidium iodide (Soft Flow, Hungary)
using flow cytometry, as described previously (Gasz et al.
2006). First, the medium was discarded and wells were
washed twice with isotonic sodium chloride solution. Cells
were removed from plates using a mixture of 0.25 % trypsin
(Sigma, Hungary), 0.2 % ethylene-diamin tetra-acetate
(EDTA; Sigma, Hungary), 0.296 % sodium citrate, and
0.6 % sodium chloride in distillated water. This medium was
applied for 15 min at 37 °C. Removed cells were washed
twice in cold PBS and were resuspended in binding buffer
containing 10mMHEPESNaOH, pH 7.4, 140mMNaCl, and
2.5 mM CaCl2. Cell count was determined in Burker’s cham-
ber for achieving a dilution in which 1 ml of solution contains
106 cells. One hundred microliters of cell suspension (105
cells) was transferred into 5 ml round-bottom polystyrene
tubes. Cells were incubated for 15 min with FITC-
conjugated annexin V molecules and propidium iodide (PI).
After this period of incubation, 400 μl of annexin-binding
buffer (BD Biosciences, USA) was added to the tubes as
described by the manufacturers. The samples were immedi-
ately measured by BD FacsCalibur flow cytometer (BD
Biosciences, USA). Results were analyzed by Cellquest soft-
ware (BD Biosciences, USA). Quadrant dot plot was intro-
duced to identify living and necrotic cells and cells in early or
late phase of apoptosis. Necrotic cells were identified as single
PI-positive. Apoptotic cells were branded as annexin V-FITC-
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positive only and cells in late apoptosis were recognized as
double-positive for annexin V-FITC and PI. Cells in each
category were expressed as percentage of the total number
of stained cells counted.
Invasion and Proliferation Assay
Cell invasion assay was performed in an invasion cham-
ber based on the Boyden chamber principle. Each cham-
ber contains an insert fitted with an 8 μM pore size
polycarbonate membrane precoated with rat tail collagen
I (5 μg/cm2). The inserts were washed in DMEM and
incubated for 30 min at room temperature. Each insert
was filled with 5×105 cells in 400 μl of serum-free
media. The following experimental groups were used:
(1) cells with no treatment and (2) cells exposed to
100 nM PACAP1-38. Cells were incubated for 72 h at
37 °C in a CO2 (5 %) incubator. After incubation,
supernatant was discarded and viable cells invaded the
collagen were stained with 400 μl of crystal violet for
20 min at room temperature. After washing, non-
invading cells were removed from the insert. Each
stained insert was transferred in a new chamber contain-
ing 200 μl of a solution of H2O/ethanol/acetic acid
(49:50:1) for 20 min at room temperature. One hundred
microliters of the dye mixture was transferred to a 96-
well microtiter plate for colorimetric measurement.
Absorbance proportional to cell concentration was deter-
mined at 560 nm.
Proliferation assay was performed on cells found in the
chambers simultaneously with invasion assay at the end of
72-h incubation. After removal of medium, 400 μl serum-free
medium containing 20 % of CellTiter 96 Aqueous One solu-
tion reagent was added to the cells. This plate was incubated
for 3 h at 37 °C in a humified, 5 % CO2 atmosphere. After
incubation, 100 μl of the medium of each well was transferred
in a 96-well plate and absorbance proportional to cell concen-
tration was determined at 560 nm using colorimetric test.
Experiments with Decidual and Peripheral Blood
Mononuclear Cells of Healthy Pregnant Women
Patients and Human Samples
All subjects were patients of the Department of Obstetrics and
Gynecology at the University of Pecs. Samples of decidual
tissues and matched peripheral blood were obtained from nine
healthy pregnant women underwent elective termination of
apparently normal pregnancies at the 6–10 weeks of gestation.
They did not have a history of spontaneous abortion, ectopic
pregnancy, preterm delivery, or stillbirth.
Written informed consent was obtained from all partici-
pants. The study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki as reflected in a priori
approval by the Regional Ethical Committee at the Faculty
of Medicine, University of Pecs.
Isolation of Decidual Mononuclear Cells
Isolation of decidual mononuclear cells (DMC) from decidual
tissue was performed as previously described (Szereday et al.
2012). Briefly, decidual tissue was cut into pieces, exposed to
collagenase IV digestion (equal volume of tissue and 0.5 %
collagenase type IV, Sigma-Aldrich Kft., Hungary) at 37 °C
for 60 min with gentle stirring on the magnetic stirrer. Cell
suspension was passed through 100 μm nylon mesh (BD
Biosciences, USA) for tissue debris elimination and centri-
fuged at 600×g for 10 min. The pellet was resuspended and
was passed through 70 μm nylon mesh (BD Biosciences,
USA). The pellet was resuspended again in RPMI 1640
(Csertex Kft., Hungary) and overlaid on Ficoll-Paque gradient
and centrifuged at 800×g for 20 min. DMC were collected
from the interface, washed, and passed through 40 μm mesh
(BD Biosciences) and resuspended 106/ml of cell culture
medium [RPMI 1640 supplemented with L-glutamine
(2 mM), penicillin (1×10−5 U/l), streptomycin sulfate
(0.05 g/l), and 10 % fetal calf serum (all from GIBCO, Life
Technologies, Hungary)].
Isolation of Decidual Lymphocytes
Isolated decidual lymphocytes (DL) were obtained as non-
adherent cell fraction of DMC cultured on 100 mm×20 mm
tissue culture Petri dish in humidified 5 % CO2 incubator at
37 °C, after the long adherence procedure (24 h).
Isolation of Peripheral Blood Mononuclear Cells
Ten milliliters of venous blood was taken. Peripheral blood
mononuclear cells (PBMC) were separated from heparinized
venous blood on Ficoll-Paque gradient. Separated peripheral
blood lymphocytes were obtained as non-adherent cell frac-
tion of PBMC cultured on 100 mm×20 mm tissue culture
Petri dish in humidified 5 % CO2 incubator at 37 °C, after the
long adherence procedure (24 h).
Cytometric Bead Array (CBA)
Concentration of cytokines from supernatants was determined
using a human Th1/Th2 CBA kit (BD Biosciences, USA)
which allowed for the simultaneous detection of IL-2, IL-4,
IL-6, IL-10, TNF-α, and IFN-γ. Aliquoted samples were
thawed and CBA analysis performed according to the manu-
facturer’s protocol. Briefly, beads coated with capture anti-
bodies were mixed. Fifty microliters of the capture bead mix-
ture was added to 50 μl of sample. To these sample-bead
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compounds, 50 μl of phycoerythrin conjugated detection
antibody was added and this mixture was incubated for 3 h
in dark at room temperature. The samples were then washed
with 1 ml of wash buffer in 1,100 rpm for 5 min and the
pellets were resuspended in 300 μl wash buffer. Cytokine
standards were serially diluted to facilitate the construction of
calibration curves necessary for determining protein concen-
trations of test samples. Flow cytometric analysis was per-
formed on a BD FACSCalibur (BD Immunocytometry
Systems, Erembodegen, Belgium) with Cell Quest software
and data were analyzed with FCS Express V3 software.
Angiogenesis Array
Supernatants of PACAP1-38-treated decidual and peripheral
blood mononuclear cells were also analyzed by angiogenesis
array as described above.
Results
Experiments on HTR-8/SVneo Cells
Cell Viability Test
Viability of HTR-8/SVneo cells after H2O2 treatment was mea-
sured byMTTassay (Fig. 1). Exposure to 150μMH2O2 for 24 h
resulted in a significant decrease in cell viability. PACAP1-38
alone had no effect on cell viability. Pretreatment with 10 or
100 nM PACAP1-38 led to significant increase in the ratio of
living cells, with no significant difference between the 10 and
100 nM concentrations of PACAP1-38 (Fig. 1a). In contrast to
these findings, simultaneous PACAP1-38 treatment showed no
effect against H2O2-induced oxidative stress (Fig. 1b).
Invasion Assay
To test the potential of PACAP on invasive behavior of HTR-
8/SVneo human first trimester extravillous trophoblast cells,
invasiveness of cells in the presence or absence of PACAP1-
38 was analyzed by cell invasion assay (Fig. 2a). PACAP1-38
treatment did not significantly alter the invasiveness of HTR-
8/SVneo trophoblast cells (Fig. 2b).
Angiogenesis Array
Cell-conditioned media of untreated or PACAP1-38 treated
HTR-8/SVneo cells were subjected to angiogenesis array
(Fig. 3a), suitable to measure protein levels of 51
angiogenesis-related molecules. Levels of several angiogenic
factors were markedly decreased in the cell culture superna-
tants after 24 h PACAP1-38 treatment. Secreted levels of
activin A, ADAMTS-1, angiogenin, angiopoietin-1, endo-
crine gland-derived vascular endothelial growth factor (EG-
VEGF), and endoglin were reduced by 69, 79, 66, 91, 45, and
55 %, respectively (Fig. 3b).
Experiments on HIPEC65 Cells
Cell Viability Tests
Viability of HIPEC 65 cells after methotrexate treatment was
measured by WST-1 assay (Fig. 4). Methotrexate treatment
significantly decreased cell survival in HIPEC 65 cells, and
this effect could not be altered by PACAP1-38. In order to
distinguish apoptotic cells from necrotic and living cells,
annexin V–propidium iodide staining was used. Similarly to
results obtained from WST-1 assay, PACAP1-38 could not
counteract the cell survival decreasing effect of MTX (Fig. 5).
Invasion and Proliferation Assay
Invasion assay performed on HIPEC 65 cells (Fig. 6) showed
that addition of PACAP1-38 decreased the invasion of the
HIPEC 65 cells and increased their proliferation.
Experiments on Decidual and Peripheral Blood Mononuclear
Cells
Angiogenesis Array
Cell-conditioned media of untreated and PACAP1-38 treated
(24 h) human peripheral blood and decidual mononuclear
cells were also analyzed by angiogenesis protein array
(Fig. 7). PACAP1-38 did not alter the secreted levels of tested
angiogenic molecules by peripheral blood (Fig. 7a) or decid-
ual (Fig. 7b) mononuclear cells.
We detected amphiregulin, endothelin-1, GM-CSF, IL-1β,
IL-8, MIP-1α, matrix metalloproteinases (MMP)-8, MMP-9,
TIMP1, CXCL4, and serpin E1 molecules in the supernatants
of peripheral blood mononuclear cells (Fig. 7a). The decidual
blood mononuclear cells also produced coagulation factor III,
DPPIV, EG-VEGF, IGFBP-1, IGFBP-2, IGFBP-3, MCP1,
and prolactin (Fig. 7b). Amphiregulin and CXCL4 were not
present in the supernatants of decidual blood mononuclear
cells (Fig. 7b).
Inflammatory Cytokine Production by Decidual
and Peripheral Blood Mononuclear Cell in Healthy
Pregnant Women
Th1 and Th2 cytokines were analyzed by CBA system.
Inflammatory cytokines production by decidual and PBMC
was not altered after PACAP1-38 or PACAP antagonist
PACAP6-38 treatment compared to control samples (Table 1).
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Discussion
The common aim of our study was to use experiments exam-
ining the possible role of PACAP related to human pregnancy.
In the first set of experiments, we investigated whether
PACAP influences cell survival of primary trophoblast cell
line exposed to H2O2-induced oxidative stress. Oxidative
stress plays an important role in placental pathology. It was
Fig. 1 Effect of PACAP1-38 (a)
pretreatment and (b) co-treatment
on viability of HTR-8/SVneo
cells as measured by MTT assay
exposed to H2O2 for 24 h. Data
are expressed as percentage of
living cells ± SEM. **p<0.01,
***p<0.001, compared to control
values; #p<0.05 compared to the
H2O2-treated groups
Fig. 2 PACAP1-38 does not alter
invasiveness of HTR-8/SVneo
trophoblast cells. a Invasion of
untreated or 1 μM PACAP1-38
treated HTR-8/SVneo cells into
the detection zones after 72 h is
shown. Cells were labeled with
calcein AM (confocal
microscope, bar 2 mm). b
Quantification of the invasion
assay. Area closure (%) is
calculated frommeasured areas of
invasion at 72 h. Data are
presented as mean ± SEM from
three wells per condition
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suggested as a contributory factor in pathological events like
miscarriage and preeclampsia (Burton and Jauniaux 2004;
Poston et al. 2011). Previously PACAP has been shown to
decrease cell viability of JAR cells originating from human
choriocarcinoma (Boronkai et al. 2009). This was rather sur-
prising given the common survival-promoting effect of
PACAP in most cell types (Vaudry et al. 2009; Reglodi et al.
2011). Here, we tested whether this effect of PACAP on cell
survival depends on the malignancy of cells. We found that
PACAP pretreatment protected nontumorous HTR-8/SVneo
trophoblast cells, hence we may conclude that PACAP shows
different effects in malignant and nonmalignant trophoblast
cells. This difference has also been described in other cells, for
example in retinal cells, where PACAP is known to enhance
survival of normal retinal cells under the influence of different
stressors (Atlasz et al. 2010), while it reduces survival of
retinoblastoma cells (Wojcieszak and Zawilska 2014). Based
on our results, it seems that the effect of PACAP on tropho-
blast cells also depends on the normal versus tumorous nature
of the cells, on environmental influences, timing of the treat-
ment, and the nature of the stressor.
We also investigated if PACAP could enhance the invasive
ability of HTR-8/SVneo and HIPEC65 trophoblast cells. We
observed that PACAP had detectable effects on invasion and
proliferation of HIPEC 65 cells, but it did not affect the
invasiveness of HTR-8/SVneo cells suggesting that its effects
depend on the cell type. Among others, MMPs, especially
MMP-2, are involved in the invasive process responsible for
implantation during pregnancy (Staun-Ram et al. 2004).
PACAP has been shown to enhance relaxin-induced secretion
of MMP-2 in rats (Teng et al. 2000), raising the possibility of
its contribution to the mechanisms of implantation. The pos-
sible explanation of its distinct effect in HTR-8/SVneo and
HIPEC 65 cells could be the signaling mechanisms leading to
cell death or survival and/or the presence/absence of different
splice variants of the PACAP receptor.
We also investigated the effects of PACAP on angiogenetic
factors. The human placenta is principally a vascular organ
that functions to achieve a physiological union of the maternal
and fetal blood supplies. A major physiological role of the
placenta is to develop an extensive vascular network allowing
for nutrient, waste, and gas exchange between the maternal
and fetal circulations. To accomplish this, the placenta pro-
duces a variety of angiogenic factors. The regulation of an-
giogenesis in pregnancy is tightly controlled. Angiogenic
growth factors such as angiogenin, angiopoietins, endoglin,
EG-VEGF, VEGF, and placental growth factor play an impor-
tant role in placental vasculogenesis and angiogenesis.
Extravillous trophoblast-derived angiogenetic factors may al-
so play a role in spiral artery remodeling as well as control of
trophoblast invasion. The balance between proangiogenic and
antiangiogenic factors modulates these processes.
Our result showed that HTR-8/SVneo cells secreted lower
levels of activin, ADAMTS-1, angiogenin, angiopoietin-1,
EG-VEGF, and endoglin after 24 h PACAP1-38 treatment.
Fig. 3 PACAP1-38 decreases the
secretion of several angiogenic
factors in trophoblast cells. a Cell
conditioned media of untreated or
1 μM PACAP1-38 (24 h) treated
HTR-8/SVneo cells analyzed by
protein array. b Densitometric
evaluation of the protein array.
Data are presented as mean ±
SEM (N=2; *p<0.05)
Fig. 4 Viability of HIPEC 65 cells as measured by WST-1 assay. Cells
were exposed to 10 μM MTX and/or 100 nM PACAP1-38, as indicated
in the figure. ***p<0.001 compared to control group
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Since placental oxygenation is an important factor in control-
ling angiogenic factor production, these data suggest that
PACAP1-38 may play an important role in the fine regulation
of angiogenesis by modulating the production of different
angiogenic factors. However, regulation of these factors by
PACAP1-38 in hypoxic conditions merit further investigation.
The immune microenvironment of the fetomaternal inter-
face is crucial for the maintenance of pregnancy, and cyto-
kines are considered to be key regulators. For many years,
Th1/Th2 hypothesis has provided a useful framework for
studies of the immunology of pregnancy. However, the find-
ings that pregnancy itself is an inflammatory state have led to a
revision of this hypothesis and now it is apparent that both
arms of the immune response are intensified during healthy
pregnancy, but with a stronger bias towards Th2 than Th1
responses. This Th2 cytokine polarization occurs both at
systemic level and at the fetal–maternal interface and the
cause behind this cytokine shift are not clearly defined.
Based on the well-known immunomodulatory actions of
the VIP–PACAP peptide family (Ganea and Delgado 2002),
we proposed that PACAP would be involved in cytokine
production of decidual cells. Recently, VIP has been shown
to be involved in recruitment of T cells during the
decidualization process (Grasso et al. 2014). In this study,
we analyzed the effect of PACAP1-38 and PACAP6-38 on
the inflammatory and proinflammatory cytokine production
of peripheral and decidual lymphocytes obtained from healthy
pregnant women. Investigating Th1 and Th2 cytokine pro-
duction by peripheral and decidual cells, we did not find any
characteristic differences after PACAP1-38 or PACAP6-38
treatment compared to the control group. These results sug-
gest that during healthy pregnancy neither in the periphery nor
at the fetomaternal interface PACAP1-38 or PACAP6-38 reg-
ulates immune microenvironment by modulating cytokine
production. Although PACAP has been described to modulate
cytokine production in several experimental paradigms both
in vitro and in vivo (Banki et al. 2013; Csanaky et al. 2014;
Nakamachi et al. 2012), it seems that PACAP does not have
such an effect on decidual lymphocytes, which further sup-
ports the finding that the actions of PACAP are dependent on
cell types and several other factors such as cycle, hormonal
status, and growth factors present in the microenvironment
(Vaudry et al. 2009; Szabo et al. 2004; Somogyvari-Vigh and
Reglodi 2004).
Based on our results, PACAP has different effects on
different placental cells. This differential effect may be the
result of the nature of the cells (normal, tumorous or chal-
lenged) or other causes of the different functions can be the
expression of different receptorial splice variants as well as the
Fig. 5 Effect of MTX and PACAP1-38 on cell survival in HIPEC 65
trophoblast cells. Distinction between living, necrotic, early, and late
apoptotic cells. Examples of dot plots (a) as determined by flow cytom-
etry following annexin V and propidium iodide double staining. Hori-
zontal axis represents annexin V intensity and vertical axis shows PI
staining. The lines divide each plot into quadrants—lower left quadrant
living cells (AnV−/PI−), lower right quadrant early apoptotic cells
(AnV+/PI−), upper left quadrant necrotic cells (AnV−/PI+), upper right
quadrant late apoptotic cells (AnV+/PI+). Graphs (b) demonstrate the
mean percentage of living cells, ratio of cells in early and late apoptosis.
*p<0.05, **p<0.01
Fig. 6 Invasion and proliferation of HIPEC 65 cells as assessed by
invasion assay based on Boyden chamber principle. Cells were treated
with PACAP1-38. *p<0.05 compared to control group
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Fig. 7 Secreted angiogenic factors by peripheral blood and decidual
mononuclear cells. a Angiogenesis array with cell-conditioned media of
untreated or 1 μM PACAP1-38 treated (24 h) peripheral blood
mononuclear cells. b Angiogenesis array with cell-conditioned media of
untreated or 1 μMPACAP1-38 treated (24 h) decidual mononuclear cells
Table 1 Cytokine production by
decidual and peripheral blood
mononuclear cells in healthy
pregnant women
pg/ml Control +PACAP1-38 +PACAP1-38+
PACAP6-38
+PACAP36-38
PBMC IL-2 734.7 742.7 755.9 753.3
IL-4 88.7 88.7 86.3 88.7
IL-6 76.8 78.5 78.5 81.6
IL-10 262.3 250 260.3 266.4
TNF-α 1,016.1 1,017.9 1,068.4 1,064.8
IFN-γ 653 644.3 729.4 665.1
Decidual
lymphocytes
IL-2 562.8 563.6 575.3 577.8
IL-4 25.9 25.9 29.3 29.3
IL-6 99.5 96.5 95 99.5
IL-10 184.5 160 160 164.1
TNF-α 814.1 767.2 783.4 823.1
IFN-γ 408.9 424.7 408.9 424.7
J Mol Neurosci
temporal and spatial distribution of the PACAP receptors in the
placenta. The expression of the different PACAP receptors in the
various placental cell types is not fully characterized yet. The
expression of PAC1 and VPAC receptors has been shown in the
placenta. The gene encoding VPAC receptors is weakly
expressed in the human placenta (Sreedharan et al. 1995). In
human placental tissues, Scaldaferri et al. (2000) found expres-
sion of the variants PAC1SV1 and SV2. Radioligand binding
studies have confirmed that PACAP is able to bind to placental
tissues (Scaldaferri et al. 2000). Koh et al. described that the
expression of PAC1 receptors shows temporal and spatial vari-
ance—PAC1 receptor mRNA expression increases with the
progression of pregnancy and varies between different cell types
and cytotrophoblast and syncytiotrophoblast cells show weaker
expression than decidual cells or chorionic vessels (Koh et al.
2005). Furthermore, a great interspecies difference also exists
between rats and humans (Koh et al. 2003, 2005; Scaldaferri
et al. 2000). A detailed mapping of the changes in receptor
expression and their splice variants would be necessary to ex-
actly verify the different effects of PACAP in the placenta
throughout the entire pregnancy.
Our present results indicate that PACAP has some effects
on mechanisms playing a role in invasiveness and implanta-
tion in certain cell types, while it has no effects on others. Our
results could be a starting point to further investigation on the
influence of PACAP on trophoblast cells.
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